Compare PNRG & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PNRG | NGEN |
|---|---|---|
| Founded | 1973 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.4M | 317.6M |
| IPO Year | 1995 | N/A |
| Metric | PNRG | NGEN |
|---|---|---|
| Price | $221.30 | $3.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 30.2K | ★ 99.9K |
| Earning Date | 04-14-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 103.81 | N/A |
| EPS | ★ 9.43 | N/A |
| Revenue | ★ $237,796,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.03 | ★ N/A |
| Revenue Growth | ★ 79.05 | N/A |
| 52 Week Low | $126.40 | $3.55 |
| 52 Week High | $238.20 | $5.93 |
| Indicator | PNRG | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 65.85 | 45.93 |
| Support Level | $159.14 | $3.69 |
| Resistance Level | N/A | $4.44 |
| Average True Range (ATR) | 9.05 | 0.29 |
| MACD | 0.98 | 0.02 |
| Stochastic Oscillator | 76.58 | 54.77 |
PrimeEnergy Resources Corp is an independent oil and natural gas company that is engaged in acquiring, developing, and producing oil and natural gas. It owns producing and non-producing properties located in Texas and Oklahoma. The company's business activities include development and exploratory drilling and providing well servicing support operations for many of the onshore oil and gas wells through its subsidiaries. It is also active in the acquisition of producing oil and gas properties through joint ventures with industry partners.
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.